KPP Advisory Services LLC Has $374,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

KPP Advisory Services LLC lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,621 shares of the biopharmaceutical company’s stock after selling 264 shares during the quarter. KPP Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $374,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of BMY. Algert Global LLC acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth $328,000. AMF Tjanstepension AB grew its position in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after buying an additional 39,419 shares during the period. Czech National Bank increased its stake in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. Czech National Bank now owns 413,002 shares of the biopharmaceutical company’s stock valued at $21,369,000 after acquiring an additional 26,718 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Bristol-Myers Squibb by 61.3% in the 3rd quarter. GAMMA Investing LLC now owns 27,386 shares of the biopharmaceutical company’s stock valued at $1,417,000 after acquiring an additional 10,410 shares during the period. Finally, Everpar Advisors LLC boosted its stake in Bristol-Myers Squibb by 4.1% during the 3rd quarter. Everpar Advisors LLC now owns 11,242 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 446 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on BMY shares. Wolfe Research started coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Bank of America restated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Morgan Stanley lifted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Finally, Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their target price for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $56.60.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $60.03 on Tuesday. The firm has a 50-day moving average of $57.60 and a 200-day moving average of $53.34. The company has a market cap of $121.76 billion, a PE ratio of -16.72, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.13%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.